Changes

EMADS is a collaborative effort of many studies to investigate the potential role of rare exomic variation on drinking and smoking phenotypes. Through the effort we hope to extend results of previous GWAS meta-analyses of drinking and smoking as well as identify novel genetic associations. As of this writing over 20 studies plan to contribute a total of 120,000 samples. Several other studies hope to contribute but, given the novelty of the exome chip genotyping array, are awaiting completion of genotyping.

EMADS is a collaborative effort of many studies to investigate the potential role of rare exomic variation on drinking and smoking phenotypes. Through the effort we hope to extend results of previous GWAS meta-analyses of drinking and smoking as well as identify novel genetic associations. As of this writing over 20 studies plan to contribute a total of 120,000 samples. Several other studies hope to contribute but, given the novelty of the exome chip genotyping array, are awaiting completion of genotyping.

We use the exome chip as the primary genotyping technology, largely because larger samples have been genotyped on the exome chip (compared to sequencing). However, studies with sequences are more than welcome and can easily be included in our current analysis efforts.

We use the exome chip as the primary genotyping technology because larger samples have been genotyped on the exome chip (compared to sequencing). However, studies with sequences are more than welcome and can easily be included in our current analysis efforts.

== Organization ==

== Organization ==